
FDA Grants Fast Track Designation to HLD-0915 in Prostate Cancer
The U.S. Food and Drug Administration (FDA) has granted fast track designation to the drug HLD-0915 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The development was announced in a news release issued by …